Calm

Phoenix Life

Product Description

Phoenix Calm is designed for managing anxiety and creating a general sense of wellbeing, without feeling overly relaxed. Further, with self managed daily doses, Phoenix Calm has been designed as an everyday tool for managing the stresses of modern day society and giving people their much needed sense of calm.

Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), CANNABIGEROL (CBG),
>0.3% TETRAHYRDRACANNABINOL (THC)
AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE,
LINALOOL , P-CYMENE, A-PINENE, B-PINENE

Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

Global Distribution Strategy

Phoenix Calm is defined under most cannabis laws with respect to sales and distribution, as an extract from Industrial Hemp. The use of these specific strains allow the product to be sold under am ever expanding global acceptance of CBD and its safety and low risk of addiction as cited by the World Health Organization. This allows for a greater level of distribution due the reduced levels of product control requirements

Online

Due the product being classified as "CBD from Industrial Hemp", this product can be sold Online and exported to over 20 countries. To facilitate this, the product will be made available as Phoenix Calm (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.

Australia

Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2024.

Europe

Online distribution under generic CBD classification. NHMA partnerships 2022 and clinical trials to be commenced in 2024.

Global Distribution

Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Calm will initially be sold Online & in National Healthcare Management Agreements.

United States

Online distribution under hemp CBD classification. Equaliti License partner-ship. Clinical trials to be commenced late 2024.

Vanuatu

Initial products to be supplied by the USA. Roll-out as part of distribution under approved NHMA.

Medical History and Development Information

Initial and ongoing studies show that the introduction of the specific dose of CBD with the included terpene profile significantly reduced levels of anxiety and created a general sense of wellbeing. Designed to provide a natural relaxation without sedation. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND ☐ Completed ☐ Next Step ☐ Not Completed

Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at https://pubmed.ncbi.nlm.nih.gov/24923339/ 2014;13(6):953-60. DOI: 10.2174/1871527313666140612114838 PMID: 24923339

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

Author(s): Alexandre R de Mello Schier, Natalia P de Oliveira Ribeiro, Danielle S Coutinho, Sergio Machado, Oscar Arias-CarriV≥n, Jose A Crippa, Antonio W Zuardi, Antonio E Nardi, Adriana C Silva

Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.

Phoenix Life Sciences Pty Ltd
Level 16, No1 Martin Place Sydney Australia

www.phoenixlife.co